Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus

References

• Zierler K. Whole body glucose metabolism. Am J Physiol. 1999;276:E409–E426.
   PubMed Web of Science ®Google Scholar
• Kowalski GM, Bruce CR. The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab. 2014;307:E859–E871.
   PubMed Web of Science ®Google Scholar
• Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34:121–138.
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32–43.
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
   PubMed Web of Science ®Google Scholar
• Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
   PubMed Web of Science ®Google Scholar
• Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem. 2009;52:1785–1794.
   PubMed Web of Science ®Google Scholar
• Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297–322.
   PubMed Web of Science ®Google Scholar
• Novikov A, Vallon V. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens. 2016;25:50–58.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90–100.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61:187–196.
   PubMed Web of Science ®Google Scholar
• Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188–F193.
   PubMed Web of Science ®Google Scholar
• Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–112.
   PubMed Web of Science ®Google Scholar
• Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013;304:E117–E130.
   PubMed Web of Science ®Google Scholar
• Schmidt UM, Eddy B, Fraser CM, et al. Isolation of (a subunit of) the Na+/D-glucose cotransporter(s) of rabbit intestinal brush border membranes using monoclonal antibodies. FEBS Lett. 1983;161:279–283.
   PubMed Web of Science ®Google Scholar
• Peerce BE, Wright EM. Conformational changes in the intestinal brush border sodium-glucose cotransporter labeled with fluorescein isothiocyanate. Proc Natl Acad Sci U S A. 1984;81:2223–2226.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330:379–381.
   PubMed Web of Science ®Google Scholar
• Turk E, Wright EM. Membrane topology motifs in the SGLT cotransporter family. J Membr Biol. 1997;159:1–20.
   PubMed Web of Science ®Google Scholar
• Tyagi NK, Kumar A, Goyal P, et al. D-Glucose-recognition and phlorizin-binding sites in human sodium/D-glucose cotransporter 1 (hSGLT1): a tryptophan scanning study. Biochemistry. 2007;46:13616–13628.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev. 1994;74:993–1026.
   PubMed Web of Science ®Google Scholar
• Hummel CS, Lu C, Loo DD, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300:C14–C21.
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1:57–92.
   PubMedGoogle Scholar
• Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
   PubMed Web of Science ®Google Scholar
• Vrhovac I, Balen ED, Klessen D, et al. Localizations of Na-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467:1881–1898.
   PubMed Web of Science ®Google Scholar
• Poppe R, Karbach U, Gambaryan S, et al. Expression of the Na+-D-glucose cotransporter SGLT1 in neurons. J Neurochem. 1997;69:84–94.
   PubMed Web of Science ®Google Scholar
• Kim HR, Park SW, Cho HJ, et al. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res. 2007;56:224–236.
   PubMed Web of Science ®Google Scholar
• Morrison AI, Panayotova-Heiermann M, Feigl G, et al. Sequence comparison of the sodium-D-glucose cotransport systems in rabbit renal and intestinal epithelia. Biochim Biophys Acta. 1991;1089:121–123.
   PubMed Web of Science ®Google Scholar
• Kashiwagi Y, Nagoshi T, Yoshino T, et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One. 2015;10:e0130605.
   Google Scholar
• Coady MJ, Pajor AM, Wright EM. Sequence homologies among intestinal and renal Na+/glucose cotransporters. Am J Physiol. 1990;259:C605–C610.
   PubMedGoogle Scholar
• Zhou L, Cryan EV, D’Andrea MR, et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90:339–346.
   PubMed Web of Science ®Google Scholar
• Banerjee SK, McGaffin KR, Pastor-Soler NM, et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84:111–118.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Inoue R, Matsumoto M, et al. Comparative expression of hexose transporters (SGLT1, GLUT1, GLUT2 and GLUT5) throughout the mouse gastrointestinal tract. Histochem Cell Biol. 2011;135:183–194.
   PubMed Web of Science ®Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306:F194–F204.
   PubMed Web of Science ®Google Scholar
• Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307:F317–F325.
   PubMed Web of Science ®Google Scholar
• Tabatabai NM, Blumenthal SS, Lewand DL, et al. Differential regulation of mouse kidney sodium-dependent transporters mRNA by cadmium. Toxicol Appl Pharmacol. 2001;177:163–173.
   PubMed Web of Science ®Google Scholar
• Lee WS, Kanai Y, Wells RG, et al. The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem. 1994;269:12032–12039.
   PubMed Web of Science ®Google Scholar
• Balen D, Ljubojevic M, Breljak D, et al. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol. 2008;295:C475–C489.
   Google Scholar
• Takata K, Kasahara T, Kasahara M, et al. Immunohistochemical localization of Na(+)-dependent glucose transporter in rat jejunum. Cell Tissue Res. 1992;267:3–9.
   PubMed Web of Science ®Google Scholar
• Haase W, Heitmann K, Friese W, et al. Characterization and histochemical localization of the rat intestinal Na(+)-D-glucose cotransporter by monoclonal antibodies. Eur J Cell Biol. 1990;52:297–309.
   PubMed Web of Science ®Google Scholar
• Sabolic I, Skarica M, Gorboulev V, et al. Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences. Am J Physiol Renal Physiol. 2006;290:F913–F926.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Korn K, Raszeja-Specht A, et al. Monoclonal antibodies against the renal Na+-D-glucose cotransporter. Identification of antigenic polypeptides and demonstration of functional coupling of different Na+-cotransport systems. J Biol Chem. 1988;263:18419–18429.
   PubMed Web of Science ®Google Scholar
• Takata K, Kasahara T, Kasahara M, et al. Localization of Na(+)-dependent active type and erythrocyte/HepG2-type glucose transporters in rat kidney: immunofluorescence and immunogold study. J Histochem Cytochem. 1991;39:287–298.
   PubMed Web of Science ®Google Scholar
• Haase W, Koepsell H. Electron microscopic immunohistochemical localization of components of Na+-cotransporters along the rat nephron. Eur J Cell Biol. 1989;48:360–374.
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Pham L, Vroman B, et al. Kinetic and molecular identification of sodium-dependent glucose transporter in normal rat cholangiocytes. Am J Physiol. 1997;272:G1168–G1174.
   Google Scholar
• Mamchaoui K, Makhloufi Y, Saumon G. Glucose transporter gene expression in freshly isolated and cultured rat pneumocytes. Acta Physiol Scand. 2002;175:19–24.
   PubMedGoogle Scholar
• Bodega F, Sironi C, Armilli M, et al. Evidence for Na+-glucose cotransporter in type I alveolar epithelium. Histochem Cell Biol. 2010;134:129–136.
   PubMed Web of Science ®Google Scholar
• Fan X, Chan O, Ding Y, et al. Reduction in SGLT1 mRNA expression in the ventromedial hypothalamus improves the counterregulatory responses to hypoglycemia in recurrently hypoglycemic and diabetic rats. Diabetes. 2015;64:3564–3572.
   PubMed Web of Science ®Google Scholar
• Yu AS, Hirayama BA, Timbol G, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010;299:C1277–C1284.
   PubMed Web of Science ®Google Scholar
• Yu AS, Hirayama BA, Timbol G, et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol. 2013;304:C240–C247.
   PubMed Web of Science ®Google Scholar
• Elfeber K, Kohler A, Lutzenburg M, et al. Localization of the Na+-D-glucose cotransporter SGLT1 in the blood-brain barrier. Histochem Cell Biol. 2004;121:201–207.
   PubMed Web of Science ®Google Scholar
• Sabino-Silva R, Freitas HS, Lamers ML, et al. Na+-glucose cotransporter SGLT1 protein in salivary glands: potential involvement in the diabetes-induced decrease in salivary flow. J Membr Biol. 2009;228:63–69.
   PubMed Web of Science ®Google Scholar
• Elfeber K, Stumpel F, Gorboulev V, et al. Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability. Biochem Biophys Res Commun. 2004;314:301–305.
   PubMed Web of Science ®Google Scholar
• Hwang ES, Hirayama BA, Wright EM. Distribution of the SGLT1 Na+/glucose cotransporter and mRNA along the crypt-villus axis of rabbit small intestine. Biochem Biophys Res Commun. 1991;181:1208–1217.
   PubMed Web of Science ®Google Scholar
• Hirayama BA, Wong HC, Smith CD, et al. Intestinal and renal Na+/glucose cotransporters share common structures. Am J Physiol. 1991;261:C296–C304.
   Google Scholar
• Sironi C, Bodega F, Porta C, et al. Expression of Na+-glucose cotransporter (SGLT1) in visceral and parietal mesothelium of rabbit pleura. Respir Physiol Neurobiol. 2007;159:68–75.
   PubMed Web of Science ®Google Scholar
• Lein ES, Hawrylycz MJ, Ao N, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168–176.
   PubMed Web of Science ®Google Scholar
• Ervin RB, Ogden CL. Consumption of added sugars among U.S. adults, 2005–2010. NCHS data brief, no 122. Hyattsville (MD): National Center for Health Statistics; 2013.
   Google Scholar
• Miyamoto K, Hase K, Taketani Y, et al. Diabetes and glucose transporter gene expression in rat small intestine. Biochem Biophys Res Commun. 1991;181:1110–1117.
   PubMed Web of Science ®Google Scholar
• Roder PV, Geillinger KE, Zietek TS, et al. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014;9:e89977.
   PubMed Web of Science ®Google Scholar
• Gouyon F, Caillaud L, Carriere V, et al. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J Physiol. 2003;552:823–832.
   PubMed Web of Science ®Google Scholar
• Vallon V, Grahammer F, Volkl H, et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A. 2005;102:17864–17869.
   PubMed Web of Science ®Google Scholar
• Martin MG, Turk E, Lostao MP, et al. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet. 1996;12:216–220.
   PubMed Web of Science ®Google Scholar
• Turk E, Zabel B, Mundlos S, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354–356.
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158–169.
   PubMed Web of Science ®Google Scholar
• Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol. 2015;308:G946–G954.
   Google Scholar
• Gribble FM. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc. 2012;71:456–462.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Ahren B. Physiology of incretins in health and disease. Rev Diabet Stud. 2011;8:293–306.
   PubMedGoogle Scholar
• Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316–3323.
   PubMed Web of Science ®Google Scholar
• Moriya R, Shirakura T, Ito J, et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab. 2009;297:E1358–E1365.
   PubMed Web of Science ®Google Scholar
• Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250–259.
   PubMed Web of Science ®Google Scholar
• Kokrashvili Z, Mosinger B, Margolskee RF. T1r3 and alpha-gustducin in gut regulate secretion of glucagon-like peptide-1. Ann N Y Acad Sci. 2009;1170:91–94.
   PubMed Web of Science ®Google Scholar
• Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2012;342:288–296.
   PubMed Web of Science ®Google Scholar
• Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–371.
   PubMed Web of Science ®Google Scholar
• Tavakkolizadeh A, Berger UV, Shen KR, et al. Diurnal rhythmicity in intestinal SGLT-1 function, V(max), and mRNA expression topography. Am J Physiol Gastrointest Liver Physiol. 2001;280:G209–G215.
   Web of Science ®Google Scholar
• Ferraris RP, Diamond J. Regulation of intestinal sugar transport. Physiol Rev. 1997;77:257–302.
   PubMed Web of Science ®Google Scholar
• Dyer J, Hosie KB, Shirazi-Beechey SP. Nutrient regulation of human intestinal sugar transporter (SGLT1) expression. Gut. 1997;41:56–59.
   PubMed Web of Science ®Google Scholar
• Rhoads DB, Rosenbaum DH, Unsal H, et al. Circadian periodicity of intestinal Na+/glucose cotransporter 1 mRNA levels is transcriptionally regulated. J Biol Chem. 1998;273:9510–9516.
   PubMed Web of Science ®Google Scholar
• Barfull A, Garriga C, Tauler A, et al. Regulation of SGLT1 expression in response to Na(+) intake. Am J Physiol Regul Integr Comp Physiol. 2002;282:R738–R743.
   Google Scholar
• Dyer J, Daly K, Salmon KS, et al. Intestinal glucose sensing and regulation of intestinal glucose absorption. Biochem Soc Trans. 2007;35:1191–1194.
   PubMed Web of Science ®Google Scholar
• Margolskee RF, Dyer J, Kokrashvili Z, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci U S A. 2007;104:15075–15080.
   PubMed Web of Science ®Google Scholar
• Veyhl M, Keller T, Gorboulev V, et al. RS1 (RSC1A1) regulates the exocytotic pathway of Na+-D-glucose cotransporter SGLT1. Am J Physiol Renal Physiol. 2006;291:F1213–F1223.
   Google Scholar
• Veyhl M, Wagner CA, Gorboulev V, et al. Downregulation of the Na(+)- D-glucose cotransporter SGLT1 by protein RS1 (RSC1A1) is dependent on dynamin and protein kinase C. J Membr Biol. 2003;196:71–81.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Leyerer M, Gorboulev V, et al. Transporter regulator RS1 (RSC1A1) coats the trans-Golgi network and migrates into the nucleus. Am J Physiol Renal Physiol. 2006;291:F1201–F1212.
   Google Scholar
• Vernaleken A, Veyhl M, Gorboulev V, et al. Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007;282:28501–28513.
   PubMed Web of Science ®Google Scholar
• Veyhl-Wichmann M, Friedrich A, Vernaleken A, et al. Phosphorylation of RS1 (RSC1A1) steers inhibition of different exocytotic pathways for glucose transporter SGLT1 and nucleoside transporter CNT1, and an RS1-derived peptide inhibits glucose absorption. Mol Pharmacol. 2016;89:118–132.
   PubMed Web of Science ®Google Scholar
• Kellett GL, Brot-Laroche E, Mace OJ, et al. Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr. 2008;28:35–54.
   PubMed Web of Science ®Google Scholar
• Naftalin RJ. Does apical membrane GLUT2 have a role in intestinal glucose uptake? F1000Res. 2014;3:304.
   PubMedGoogle Scholar
• Chaudhry RM, Scow JS, Madhavan S, et al. Acute enterocyte adaptation to luminal glucose: a posttranslational mechanism for rapid apical recruitment of the transporter GLUT2. J Gastrointest Surg. 2012;16:312–319.
   PubMed Web of Science ®Google Scholar
• Martin MG, Wang J, Solorzano-Vargas RS, et al. Regulation of the human Na(+)-glucose cotransporter gene, SGLT1, by HNF-1 and Sp1. Am J Physiol Gastrointest Liver Physiol. 2000;278:G591–G603.
   PubMedGoogle Scholar
• Subramanian S, Glitz P, Kipp H, et al. Protein kinase-A affects sorting and conformation of the sodium-dependent glucose co-transporter SGLT1. J Cell Biochem. 2009;106:444–452.
   PubMed Web of Science ®Google Scholar
• Hirsch JR, Loo DD, Wright EM. Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes. J Biol Chem. 1996;271:14740–14746.
   PubMed Web of Science ®Google Scholar
• Ikari A, Harada H, Takagi K. Role of actin in the cAMP-dependent activation of sodium/glucose cotransporter in renal epithelial cells. Biochim Biophys Acta. 2005;1711:20–24.
   PubMed Web of Science ®Google Scholar
• Elvira B, Honisch S, Almilaji A, et al. Up-regulation of Na(+)-coupled glucose transporter SGLT1 by caveolin-1. Biochim Biophys Acta. 2013;1828:2394–2398.
   PubMed Web of Science ®Google Scholar
• Sopjani M, Bhavsar SK, Fraser S, et al. Regulation of Na+-coupled glucose carrier SGLT1 by AMP-activated protein kinase. Mol Membr Biol. 2010;27:137–144.
   PubMed Web of Science ®Google Scholar
• Gabler NK, Radcliffe JS, Spencer JD, et al. Feeding long-chain n-3 polyunsaturated fatty acids during gestation increases intestinal glucose absorption potentially via the acute activation of AMPK. J Nutr Biochem. 2009;20:17–25.
   PubMed Web of Science ®Google Scholar
• Walker J, Jijon HB, Diaz H, et al. 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. Biochem J. 2005;385:485–491.
   PubMed Web of Science ®Google Scholar
• Dieter M, Palmada M, Rajamanickam J, et al. Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obes Res. 2004;12:862–870.
   PubMedGoogle Scholar
• Shojaiefard M, Strutz-Seebohm N, Tavare JM, et al. Regulation of the Na(+), glucose cotransporter by PIKfyve and the serum and glucocorticoid inducible kinase SGK1. Biochem Biophys Res Commun. 2007;359:843–847.
   PubMed Web of Science ®Google Scholar
• Grahammer F, Henke G, Sandu C, et al. Intestinal function of gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1114–G1123.
   PubMed Web of Science ®Google Scholar
• Lang F, Klingel K, Wagner CA, et al. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci U S A. 2000;97:8157–8162.
   PubMed Web of Science ®Google Scholar
• Sandu C, Rexhepaj R, Grahammer F, et al. Decreased intestinal glucose transport in the sgk3-knockout mouse. Pflugers Arch. 2005;451:437–444.
   PubMed Web of Science ®Google Scholar
• Vayro S, Silverman M. PKC regulates turnover rate of rabbit intestinal Na+-glucose transporter expressed in COS-7 cells. Am J Physiol. 1999;276:C1053–C1060.
   PubMed Web of Science ®Google Scholar
• Castaneda-Sceppa C, Subramanian S, Castaneda F. Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity. J Cell Biochem. 2010;109:1109–1117.
   PubMed Web of Science ®Google Scholar
• Osswald C, Baumgarten K, Stumpel F, et al. Mice without the regulator gene Rsc1A1 exhibit increased Na+-D-glucose cotransport in small intestine and develop obesity. Mol Cell Biol. 2005;25:78–87.
   PubMed Web of Science ®Google Scholar
• Korn T, Kuhlkamp T, Track C, et al. The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells. J Biol Chem. 2001;276:45330–45340.
   PubMed Web of Science ®Google Scholar
• Filatova A, Leyerer M, Gorboulev V, et al. Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location. Traffic. 2009;10:1599–1618.
   PubMed Web of Science ®Google Scholar
• Elvira B, Blecua M, Luo D, et al. SPAK-sensitive regulation of glucose transporter SGLT1. J Membr Biol. 2014;247:1191–1197.
   PubMed Web of Science ®Google Scholar
• Yarandi SS, Hebbar G, Sauer CG, et al. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27:269–275.
   PubMed Web of Science ®Google Scholar
• Ducroc R, Guilmeau S, Akasbi K, et al. Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1. Diabetes. 2005;54:348–354.
   PubMed Web of Science ®Google Scholar
• Ogata H, Seino Y, Harada N, et al. KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. J Endocrinol. 2014;222:191–200.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Kojima H, Hidaka H, et al. Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Diabetologia. 1998;41:1459–1466.
   PubMed Web of Science ®Google Scholar
• Dyer J, Wood IS, Palejwala A, et al. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G241–G248.
   PubMed Web of Science ®Google Scholar
• Layman DK, Clifton P, Gannon MC, et al. Protein in optimal health: heart disease and type 2 diabetes. Am J Clin Nutr. 2008;87:1571S–1575S.
   PubMed Web of Science ®Google Scholar
• Vestri S, Okamoto MM, De Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol. 2001;182:105–112.
   PubMed Web of Science ®Google Scholar
• Tabatabai NM, Sharma M, Blumenthal SS, et al. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009;83:e27–e30.
   PubMedGoogle Scholar
• Vidotti DB, Arnoni CP, Maquigussa E, et al. Effect of long-term type 1 diabetes on renal sodium and water transporters in rats. Am J Nephrol. 2008;28:107–114.
   PubMed Web of Science ®Google Scholar
• Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000;49:990–995.
   PubMed Web of Science ®Google Scholar
• Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943–948.
   PubMed Web of Science ®Google Scholar
• Dominguez JH, Camp K, Maianu L, et al. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol. 1994;266:F283–F290.
   PubMed Web of Science ®Google Scholar
• Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13:983–988.
   PubMed Web of Science ®Google Scholar
• Mandel LJ. Metabolic substrates, cellular energy production, and the regulation of proximal tubular transport. Annu Rev Physiol. 1985;47:85–101.
   PubMed Web of Science ®Google Scholar
• Vallon V, Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens. 2010;19:425–431.
   PubMed Web of Science ®Google Scholar
• Vallon V, Grahammer F, Richter K, et al. Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol. 2001;12:2003–2011.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
   PubMed Web of Science ®Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613–621.
   PubMed Web of Science ®Google Scholar
• Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669–672.
   PubMed Web of Science ®Google Scholar
• Powell DR, DaCosta CM, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther. 2014;350:232–242.
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351–375.
   PubMed Web of Science ®Google Scholar
• Albertoni Borghese MF, Majowicz MP, Ortiz MC, et al. Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment. Nephron Physiol. 2009;112:45–52.
   Google Scholar
• Marks J, Carvou NJ, Debnam ES, et al. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol. 2003;553:137–145.
   PubMed Web of Science ®Google Scholar
• Goestemeyer AK, Marks J, Srai SK, et al. GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration. Diabetologia. 2007;50:2209–2217.
   PubMed Web of Science ®Google Scholar
• Ghezzi C, Wright EM. Regulation of the human Na+ dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol. 2012;303:C348–C354.
   PubMed Web of Science ®Google Scholar
• Lang F, Bohmer C, Palmada M, et al. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006;86:1151–1178.
   PubMed Web of Science ®Google Scholar
• Ackermann TF, Boini KM, Volkl H, et al. SGK1-sensitive renal tubular glucose reabsorption in diabetes. Am J Physiol Renal Physiol. 2009;296:F859–F866.
   PubMed Web of Science ®Google Scholar
• Han HJ, Lee YJ, Park SH, et al. High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol. 2005;288:F988–F996.
   PubMed Web of Science ®Google Scholar
• Schwenk RW, Luiken JJ, Bonen A, et al. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008;79:249–258.
   PubMed Web of Science ®Google Scholar
• Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213–3223.
   PubMed Web of Science ®Google Scholar
• Asghar O, Al-Sunni A, Khavandi K, et al. Diabetic cardiomyopathy. Clin Sci (Lond). 2009;116:741–760.
   PubMed Web of Science ®Google Scholar
• Abel ED, Kaulbach HC, Tian R, et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest. 1999;104:1703–1714.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Hardin D, Juhaszova M, et al. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol. 1993;264:H837–H844.
   PubMed Web of Science ®Google Scholar
• Belke DD, Larsen TS, Gibbs EM, et al. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2000;279:E1104–E1113.
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Cui L, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106:2125–2131.
   PubMed Web of Science ®Google Scholar
• Pereira RO, Wende AR, Olsen C, et al. GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. J Mol Cell Cardiol. 2014;72:95–103.
   PubMed Web of Science ®Google Scholar
• Pereira RO, Wende AR, Olsen C, et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc. 2013;2:e000301.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. J Diabetes Investig. 2014;5:623–634.
   PubMed Web of Science ®Google Scholar
• Balteau M, Tajeddine N, de MC, et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res. 2011;92:237–246.
   PubMed Web of Science ®Google Scholar
• Mellor KM, Varma U, Stapleton DI, et al. Cardiomyocyte glycophagy is regulated by insulin and exposure to high extracellular glucose. Am J Physiol Heart Circ Physiol. 2014;306:H1240–H1245.
   Google Scholar
• Shearer J, Ross KD, Hughey CC, et al. Exercise training does not correct abnormal cardiac glycogen accumulation in the db/db mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab. 2011;301:E31–E39.
   Web of Science ®Google Scholar
• Ramratnam M, Sharma RK, D’Auria S, et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 2014;3(4). pii:e000899.
   PubMed Web of Science ®Google Scholar
• Banerjee SK, Wang DW, Alzamora R, et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol. 2010;49:683–692.
   PubMed Web of Science ®Google Scholar
• Petersen C. Analyse des Phloridzins. Annales Academie Science Francaise. 1835;15:178.
   Google Scholar
• Castaneda F, Burse A, Boland W, et al. Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes. Int J Med Sci. 2007;4:131–139.
   PubMedGoogle Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–38.
   PubMed Web of Science ®Google Scholar
• Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181–1188.
   PubMed Web of Science ®Google Scholar
• Goodwin NC, Mabon R, Harrison BA, et al. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J Med Chem. 2009;52:6201–6204.
   PubMed Web of Science ®Google Scholar
• Powell DR, Smith MG, Doree DD, et al. LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2. Pharmacol Res Perspect. 2015;3:e00129.
   Google Scholar
• Fushimi N, Teranishi H, Shimizu K, et al. Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1). Bioorg Med Chem. 2013;21:748–765.
   PubMed Web of Science ®Google Scholar
• Fushimi N, Fujikura H, Shiohara H, et al. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. Bioorg Med Chem. 2012;20:6598–6612.
   PubMed Web of Science ®Google Scholar
• Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia. 2003;46(Suppl 1):M17–M21.
   Google Scholar
• O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100:899–904.
   PubMed Web of Science ®Google Scholar
• Schulze C, Bangert A, Kottra G, et al. Inhibition of the intestinal sodium-coupled glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood glucose levels in mice and humans. Mol Nutr Food Res. 2014;58:1795–1808.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161.
   PubMed Web of Science ®Google Scholar
• Oguma T, Nakayama K, Kuriyama C, et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther. 2015;354:279–289.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510–1515.
   PubMed Web of Science ®Google Scholar
• Wright EM. I. Glucose galactose malabsorption. Am J Physiol. 1998;275:G879–G882.
   PubMed Web of Science ®Google Scholar
• Kiela PR, Xu H, Ghishan FK. Apical NA+/H+ exchangers in the mammalian gastrointestinal tract. J Physiol Pharmacol. 2006;57(Suppl 7):51–79.
   PubMed Web of Science ®Google Scholar
• Joshi SR, Standl E, Tong N, et al. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother. 2015;16:1959–1981.
   PubMed Web of Science ®Google Scholar
• Cai Q, Li B, Yu F, et al. Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db/db mice by quantitative proteomics. J Diabetes Res. 2013;2013:263845.
   PubMed Web of Science ®Google Scholar
• Gribble FM, Williams L, Simpson AK, et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52:1147–1154.
   PubMed Web of Science ®Google Scholar